A case of severe hyperthermia after administration of methylphenidate

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 299-300

  Peyre, Hugo ^a   Delorme, Richard ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CYAMEMAZINE; METHYLPHENIDATE; PERICIAZINE; RISPERIDONE;

APGAR SCORE; BODY WEIGHT; CASE REPORT; CESAREAN SECTION; CHILD; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG EFFECT; DRUG WITHDRAWAL; EXTRACELLULAR SPACE; FAMILY LIFE; FOSTER CARE; HUMAN; HYPERACTIVITY; HYPERTHERMIA; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; INTENSIVE CARE UNIT; LETTER; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT WITHDRAWAL; TWINS;

CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEVER; HUMANS; INTELLECTUAL DISABILITY; MALE; METHYLPHENIDATE; SEVERITY OF ILLNESS INDEX;

EID: 84857865069     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182499677     Document Type: Letter

References (15)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
2. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459-474, xi. (Pubitemid 351258356)
3. Basil B, Mathews M, Budur K. Methylphenidate-induced neuroleptic malignant syndrome: a case report. Prim Care Companion J Clin Psychiatry. 2006;8(1):47. (Pubitemid 44371601)
4. Ehara H, Maegaki Y, Takeshita K. Neuroleptic malignant syndrome and methylphenidate. Pediatr Neurol. 1998;19(4):299-301. (Pubitemid 28514118)
5. Talbot JS, Ahuja AS. Near-fatal methylphenidate misuse. Br J Psychiatry 2001;178:278.
6. Kiyatkin EA. Brain temperature homeostasis: physiological fluctuations and pathological shifts. Front Biosci. 2010;15:73-92.
7. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161(4):677-684. (Pubitemid 38445512)
8. Nagashima M, Yamada K, Kimura H, et al. Hyperthermia induced by the dopamine D1 receptor agonist SK&F38393 in combination with the dopamine D2 receptor agonist talipexole in the rat. Pharmacol Biochem Behav. 1992;43(4):993-997.
9. Easton N, Marsden CA. Ecstasy: are animal data consistent between species and can they translate to humans? Journal of psychopharmacology (Oxford. J Psychopharmacol (Oxford, England). 2006;20(2):194-210.
10. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxy methamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav. 2008;90(2):198-207. (Pubitemid 351787346)
11. Mechan AO, Esteban B, O'Shea E, et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol. 2002;135(1):170-180. (Pubitemid 34102110)
12. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032-2037. (Pubitemid 27176139)
13. Shioda K, Nisijima K, Yoshino T, et al. Effect of risperidone on acute methamphetamine-induced hyperthermia in rats. Drug Alcohol Depend. 2010;111(3):241-249.
14. Breggin PR. Psychostimulants in the treatment of children diagnosed with ADHD: risks and mechanism of action. Int J Risk Saf Med. 1999;12(1):3-35. (Pubitemid 29304896)
15. Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42(3):288-294. (Pubitemid 39592084)